Introduction
Beneficial effects of bacterial infection on tumours have been observed since the 18th century. Physicians have recorded hundreds of cases of spontaneous regression of many types of malignancies following bacterial infections (reviewed by Naut 1 ). These observations led to use of anaerobic bacteria in the treatment of cancer. For example, significantly lower recurrence and metastases were recorded in sarcoma patients with either spontaneous or inoculated concurrent streptococcal infection (Odier, 1909) . 1 In the 1960s, anaerobic bacteria were shown to target tumours and replicate within the hypoxic and necrotic regions of these tumours. Clostridium was shown to be effective in causing tumour regression in rodent models, [2] [3] [4] but a subsequent clinical trial failed to demonstrate any benefit 5 that would outweigh toxicity. More recently, this concept has been re-evaluated using attenuated strains of Salmonella 6, 7 and Clostridium. [8] [9] [10] A genetically attenuated strain of Salmonella (VNP20009) 7 was recently used in a clinical trial.
11 VNP20009 demonstrated marked toxicity when injected above 3 Â 10 8 CFU/m 2 . At this dose, some tumour colonization was observed but objective tumour regression was not observed in any of the patients, 11 suggesting that the safety features of the formulation need to be improved to be able to reach a therapeutically relevant dose.
In the current study, we investigate a different approach in which nonreplicating, nonpathogenic bacteria (E. coli strains) are genetically modified to provide a therapeutic benefit. E. coli are normally extracellular bacteria. However, a diaminopimelic acid (dap) auxotrophic strain of E. coli (BM2710) has been engineered 12, 13 that contains a plasmid with the inv gene 14 from Yersinia pseudotuberculosis and the hly locus 15 from Listeria monocytogenes. Introduction of the inv gene confers the ability to invade some nonprofessional phagocytic epithelial cells by simple co-incubation. Cell-surface expression by E. coli of the inv gene product (invasin) enables selective uptake of E. coli by mammalian cells. 12, 13 Binding of invasin to b1-integrin is necessary and sufficient to induce phagocytosis of the bacteria. 14 After internalization, E. coli is taken into phagosome/ lysosome where lysis of the bacterium occurs. Among the various bacterial proteins released into the lysosomal vesicle, the hly gene product (listeriolysin O, LLO), present in the cytoplasm of the invasive E. coli, 12 can gain access to the phagosomal membrane. LLO is a member of the pore-forming cytolysins capable of binding and perforating phagosomal membranes at low pH (reviewed by Beauregard et al 16 and Provada and Lee 17 ). The cytoplasmic contents of the bacteria can then escape into the cytosolic compartment of the mammalian cell through the pores generated by LLO. Using this mechanism, it was demonstrated 12 that invasive E. coli could be used as gene delivery vectors. In the present study, we investigate the potential of these invasive E. coli as a delivery vector of therapeutic molecules (genes or proteins), both in vitro and in vivo.
Results

Invasive bacteria exert minimal toxicity on mammalian cells
In order to assess the potential toxicity of these invasive bacteria, Caco-2 or HeLa cells were incubated with various concentrations of bacteria and cell survival was determined by Trypan blue exclusion 2 h after invasion. In these conditions, no toxicity was observed with either E. coli BM2710 harbouring plasmid pGB2Oinv or pGB2Oinv-hly at MOIs (ratio bacteria/mammalian cells) between 0.1 and 100 (not shown). To assess the 'longterm', overall toxicity of the procedure, an MTT assay was used, 48 h after bacterial invasion. At an MOI of 100 or below, no significant toxicity was observed when Caco-2 cells were incubated with E. coli BM2710 harbouring plasmid pGB2Oinv bacteria ( Figure 1a ) and only a modest toxicity could be detected at an MOI of 1000 with 75% of cell survival. By contrast, when Caco-2 cells were invaded by E. coli BM2710 harbouring plasmid pGB2Oinv-hly at an MOI of 1000, high levels of toxicity were observed (Figure 1a) . However, no statistically significant toxicity was observed at an MOI of 100 or below with E. coli BM2710 harbouring plasmid pGB2Oinv-hly (Figure 1a) . Similar results were obtained on different epithelial cells lines (Panc-02, SW979, T84, SW850, PT45, Panc-1, not shown). HeLa cells appeared to be more sensitive as the threshold of LLO-mediated toxicity was reached at an MOI of 50 (Figure 1b) . At higher MOI, the LLO-mediated toxicity was statistically significantly increased compared to E. coli BM2710 harbouring plasmid pGB2Oinv bacteria (Po0.05 at an MOI of 100 and Po0.001 at an MOI of 200). Altogether, these data suggest that the LLO protein produced by the hly locus can be toxic to epithelial cells at high concentrations and that for most cell lines, invasive E. coli can be used at MOIs equal to or below a toxicity threshold of 100.
Delivery of proteins and genes by invasive E. coli
To compare the potential of invasive E. coli to deliver genes or proteins to mammalian cells, E. coli BM2710 pGB2Oinv-hly/Prok.GFP (harbouring the plasmid pAT505, in which a prokaryotic promoter controls GFP expression 9) or E. coli BM2710 pGB2Oinv-hly/Euk.GFP (harbouring the plasmid pEGFP-C1 that directs GFP expression from an eukaryotic promoter) were incubated with Caco-2 cells. At 48 h after invasion, the cells were harvested and the percentage of GFP-positive cells was determined by flow cytometry. Figure 2 shows that more than 80% of the Caco-2 cells were GFP positive when invaded by E. coli BM2710 pGB2Oinv-hly/Prok.GFP, while around 5% were GFP positive following invasion by E. coli BM2710 pGB2Oinv-hly/Euk.GFP at an MOI compatible with mammalian cell viability. These results clearly indicate that invasive E. coli are more efficient at delivering proteins than genes. Gene transfer efficacy has already been shown to vary in different cell lines, 12 and similar differences between protein and gene transfer were observed on a large panel of epithelial cell lines (not shown). 
Expression of b1-integrin is required for invasion
To characterize the tropism of the invasive E. coli, the mouse cell line GD25, derived from the embryonic stem clone G201, where a null mutation was introduced in the b1-integrin gene, 18 was used in parallel with its isogenic counterpart GD25-b1A, stably transfected with the b1-integrin cDNA. 19 Both cell lines were incubated with E. coli BM2710 pGB2Oinv-hly/lacZ (MOI ¼ 10), and the LacZ staining presented in Figure 3a shows that GD25 were resistant to invasion, while GD25-b1A were invaded by the invasive E. coli (Figure 3b) . Therefore, our data suggest that bacterial invasion, without severe toxicity, can be achieved in the large majority of cells in which b1-integrin is expressed and accessible.
Effect of bacterial invasion on the sensitivity of Caco-2 cells to 6-methylpurine-2 0 -deoxyriboside 6-Methylpurine-2 0 -deoxyriboside (6-MPDR) has been used in various gene therapy studies. This compound can be metabolized into the toxin 6-methyl purine (MeP) by the product of the E. coli gene deoD: purine nucleoside phosphorylase (PNP). [20] [21] [22] Therefore, we hypothesized that bacterial invasion could sensitize Caco-2 cells to 6-MPDR. Caco-2 cells were invaded for 2 h with E. coli BM2710 pGB2Oinv or E. coli BM2710 pGB2Oinv-hly at an MOI of 100. The cells were then extensively washed and exposed to various concentrations of 6-MPDR. Cell survival was measured 5 days (Figure 4a ) or 10 days (Figure 4b ) after invasion. The ED 50 (effective dose to kill 50% of the cells) of 6-MPDR for noninvaded Caco-2 cells was approximately 100 mM. When Caco-2 cells were invaded by E. coli BM2710 pGB2Oinv or E. coli BM2710 pGB2Oinv-hly, the ED 50 decreased significantly to 6 mM (Po0.01) or 1.5 mM (Po0.01), respectively (Figure 4a ). These data indicate that bacterial invasion can sensitize mammalian cells to the action of 6-MPDR and that transfer of E. coli protein content to the cytosol through expression of LLO enhances this effect. Incubation of Caco-2 cells invaded by E. coli BM2710 pGB2Oinv-hly (MOI of 100) with 10 mM 6-MPDR resulted in death of 490% of cells when the incubation was prolonged to 10 
Effect of bacterial invasion on the sensitivity of mammalian cells to 5-fluorouracil
The protein encoded by the E. coli upp gene is uracil phosphoribosyltransferase (UPRT). This enzyme, expressed naturally in E. coli, converts the chemotherapeutic drug 5-fluorouracil (5-FU) into 5-fluorouridine monophosphate, a highly toxic compound. Adenoviral delivery of the upp gene has been shown to increase the sensitivity of human cancer cell lines to 5-FU 23, 24 . To assess whether bacterial invasion can lead to sensitization to 5-FU, HeLa cells were incubated for 2 h with E. coli BM2710 pGB2Oinv-hly at an MOI of 50 (an MOI compatible with survival; Figure 1b) . The cells were then extensively washed and exposed to various concentrations of 5-FU. As demonstrated in Figure 5a , invasion of HeLa cells resulted in sensitization to 5-FU (ED 50 of 6 mM with E. coli BM2710 pGB2Oinv-hly-invaded HeLa versus ED 50 of 70 mM with control HeLa cells).
Caco-2 cells appear to be resistant to 5-FU, as illustrated by the fact that around 50% of the cells remain viable after treatment with 100 mM of the drug (Figure 5b ). Invasion of Caco-2 with E. coli BM2710 pGB2Oinv-hly at an MOI of 100 failed to sensitize these cells to 5-FU ( Figure 5b ). To determine whether Caco-2 cells could be rendered sensitive to 5-FU by delivering increasing amounts of UPRT, a bacterial strain overexpressing the upp gene was generated (E. coli BM2710 pGB2Oinv-hly/upp). An upp PCR product was cloned inframe with a polyhistidine tag in the prokaryotic expression vector pBAD (Invitrogen). Expression of the tagged upp gene was checked by Western blot (not shown) using the Anti-Xpress TM antibody (Invitrogen) able to recognize the tag. The resulting bacteria were used to invade Caco-2 cells. E. coli BM2710 pGB2Oinv-hly/upp sensitized Caco-2 cells to the action of 5-FU, as demonstrated by the dramatic decrease of ED 50 from 10-100 mM (control Caco-2 cells) to 0.01-0.1 mM (Figure 5b ).
In vivo protein delivery
To assess whether protein delivery via E. coli could occur in vivo, mouse melanoma B16 cells were injected subcutaneously into C57/B6J mice. When the tumours reached 0.7-1 cm 3 , noninvasive or invasive E. coli expressing b-galactosidase (E. coli BM2710 lacZ or E. coli BM2710 pGB2Oinv/lacZ) were injected into the tumours ( Figure 6 ). No signs of systemic toxicity were observed when 5 Â 10 6 bacteria were injected. At 24 h postinjection, b-galactosidase staining could not be detected when PBS (Figure 6a) or noninvasive E. coli were used ( Figure  6b ). By contrast, b-galactosidase staining was diffuse throughout the tumour (Figure 6c ) and appeared intracellular when invasive E. coli were injected ( Figure  6d ). This staining was still detectable 4 days after injection, with reduced numbers of stained areas by 96 h (not shown).
In vivo sensitization of tumours to 6-MPDR
Subcutaneous Panc-02 tumours in C57/B6J mice were injected with PBS or E. coli BM2710 pGB2Oinv-hly, followed 2 h later by intraperitoneal (i.p.) injection of PBS or 6-MPDR. The intratumoral (i.t.) injections were repeated five times at 48 h intervals and the i.p. injections were administered a further 10 times at 24 h intervals. In tumours treated with PBS, co-administration of 6-MPDR did not significantly alter tumour progression ( Figure 7) . Similarly, i.t. administration of invasive bacteria did not significantly alter the size of the tumours when PBS was given i.p. (eg mean tumour volume at day 18 in PBS/ PBS-treated animals 1.14 versus 1.12 cm 3 in E. coli BM2710 pGB2Oinv-hly-treated animals). However, the tumour Invasive E. coli as a therapeutic delivery vector RJ Critchley et al progression was significantly inhibited by i.t. injection of E. coli BM2710 pGB2Oinv-hly followed by i.p. administration of 6-MPDR (tumour volumes at day 18: E. coli pGB2Oinv-hly/PBS 1.12 cm 3 ; E. coli pGB2Oinv-hly/6-MPDR 0.45 cm 3 ; Student's t-test: P ¼ 0.033).
Infiltrating cells and necrosis
Panc-02 tumours were treated with either PBS i.t. /PBS i.p., E. coli BM2710 pGB2Oinv-hly i.t./PBS i.p. or E. coli BM2710 pGB2Oinv-hly i.t./6-MPDR i.p. After 3 days, the tumours were excised, fixed, sectioned and stained with haematoxylin and eosin (Figure 8) . The percentage necrosis of the tumours was scored by viewing the haematoxylin-and eosin-stained tumour sections by microscopy and estimating the percentage area of necrosis in each section. Tumours injected with PBS remained largely intact, with less than 5% of necrosis (Figure 8a ), while i.t. injection of E. coli BM2710 pGB2Oinv-hly i.t. and PBS i.p. induced necrosis in up to 50% of the tumour mass (Figure 8b ). Co-administration of invasive E. coli i.t. and 6-MPDR i.p. resulted in a further increase in detectable necrosis area that was evaluated to represent around 70% of the tumour ( Figure  8c) . Altogether, these data (Figures 7 and 8 ) demonstrate that treatment of the tumours with invasive bacteria and subsequent prodrug administration can slow down the progression of tumours and that these tumours are constituted of large necrotic regions.
Inflammatory cells, mainly neutrophils and some eosinophils, were observed in the necrotic areas of tumours injected with invasive E. coli, and at the border of necrotic and viable tumour areas, neutrophils and eosinophils appeared to have infiltrated the viable tumour mass (not shown).
The presence of macrophages in these sections was determined using an anti-F4/80 antibody, which binds a 160 kDa glycoprotein expressed at the surface of murine macrophages (Serotec, Oxford, UK). The immunohistochemical (IHC) staining of macrophages revealed widespread distribution of macrophages throughout the tumours injected with invasive E. coli (Figure 9b ) compared to a minimal number observed in PBS-treated tumours (Figure 9a ). High densities of macrophages were visualized in the necrotic areas, with infiltration into the viable areas. In tumours treated with E. coli BM2710 pGB2Oinv-hly, the infiltration of macrophages appeared marginally greater in animals injected i.p. with 6-MPDR as opposed to PBS (not shown). However, as the tumours treated with E. coli BM2710 pGB2Oinv-hly plus 6-MPDR had larger areas of necrosis (Figure 8 ), the overall number of macrophages present in those tumours was greater.
The presence of dendritic cells (DCs) was detected using an antibody against CD205, a 205 kDa glycoprotein expressed at the surface of DCs, essential for the capture of antigens by DCs and upregulated upon activation of DCs. 25 DCs were also identified by their characteristic feint spindle-shaped nucleus and finger-like extensions. Invasive E. coli as a therapeutic delivery vector RJ Critchley et al Figure 10a shows that DCs were not detected in Panc-02 tumours injected with PBS, while they were detected in tumours injected with E. coli BM2710 pGB2Oinv-hly and i.p. administration of 6-MPDR (Figure 10b ) or PBS or (not shown). These DCs were essentially localized in the vicinity of the interface between necrotic and viable tumour regions.
Discussion
Recombinant E. coli have already been described as protein delivery vectors for professional phagocytic cells (ie macrophages, 26 in mouse DCs 27 and human monocyte-derived DCs). 28 E. coli coexpressing LLO and a model antigen (truncated chicken ovalbumin, OVA) were incubated with the cells, taken up and presentation of the OVA epitope on MHC class I was observed. 26, 27 In addition, an antitumour effect was observed when these bacteria were used in a vaccination protocol. 27 Similar in vitro data were obtained when human DCs were used to present MART-1 antigen epitopes. 28 In the present communication, we have used an invasive E. coli to deliver therapeutically relevant molecules to mouse and human nonprofessional phagocytic cells. We demonstrate that protein delivery is much more efficient than gene delivery. This E. coli has been engineered to express the invasin protein from Y. pseudotuberculosis. Upon invasion, up to 100% of the mammalian cells can be transduced with very limited toxicity (Figures 1 and 2) . Coexpression in E. coli inv of the LLO protein encoded by the hly locus of L. monocytogenes is associated with increased toxicity (Figure 1) . But, at nontoxic doses, LLO increases the length of time during which a reporter protein is detectable (not shown) as well as in vitro therapeutic effect (Figure 4a ). These effects are likely to be the result of the phagosomal pore-forming activity of LLO 13, 16, 17, 26, 27 that allows escape of the proteins expressed in bacteria into the cytosol (not shown) and therefore reduces their destruction in the lysosomal vesicle. 
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In addition to the delivery of recombinant proteins, we demonstrate that naturally expressed bacterial proteins with potential therapeutic applications can also be delivered to mammalian cells via this system. The E. coli enzymes deoD and upp have been used in gene therapy studies, and adenovirus-mediated expression of these genes has been shown to sensitize mammalian cells to 6-MPDR [20] [21] [22] and 5-FU, 23, 24 respectively. Invasion with E. coli sensitized Caco-2 cells to 6-MPDR ( Figure 4) and HeLa cells to the action of 5-FU (Figure 5a ). The 5-FUresistant Caco-2 cells could also be sensitized to the action of 5-FU by overexpression of the upp gene in the bacteria prior to invasion and exposure to the drug (Figure 5b) .
The real benefit of invasin expression in the bacteria is clearly demonstrated in Figure 6 , which shows that invasive E. coli can deliver the LacZ protein in vivo, in an experimental tumour. LacZ staining was still detectable 96 h after i.t. injection of invasive E. coli (not shown) but no signal was detectable 24 h after injection of noninvasive bacteria ( Figure 6 ). This in vivo protein delivery was not accompanied by systemic toxicity at the dose of bacteria used, but local zones of necrosis were observed in the tumour.
When 6-MPDR was administered by i.p. injection, a growth reduction of the tumours injected with E. coli BM2710 pGB2Oinv-hly was observed (Figure 7 ). This effect was associated with large areas of necrosis in the tumour mass ( Figure 8 ) and infiltration of inflammatory cells, namely neutrophils, eosinophils, macrophages and DCs (Figures 9 and 10 and not shown) . The concomitant presence of apoptotic/necrotic cells, bacterial products such as lipopolysaccharides 29 and bacterial DNA 30 could act as 'danger signals' 31, 32 for these infiltrating cells. The local abundance of these danger signals associated with the phagocytosis of dead cancer cells by activated macrophages and DCs is likely to initiate an immune response against specific cancer antigens. This is probably responsible for the 50% necrotic content of a tumour treated with invasive bacteria but injected i.p. with PBS. More importantly, this process could be exploited to induce an immune response against distant metastatic sites. This approach will be facilitated by the development of new generations of invasive E. coli strains. For example, the inv and/or hly genes could be inserted in the bacterial genome. This would give the opportunity to use the plasmid carrying these genes in the current bacterial versions to clone and express therapeutically relevant genes, such as other prodrug-converting enzymes or cytokines, and to apply a 'mix and match' approach to optimize a bacterial formulation.
In the current invasive E. coli, the invasion is strictly restricted to b1-integrin-expressing cells (Figure 3) . However, in some tumours, such as breast adenocarcinomas, it has been demonstrated that b1-integrin expression is decreased in a manner that correlates with the stage of differentiation. 33 This observation potentially restricts the spectrum of use of the current invasive bacteria but it may be possible to express retargeting molecules such as single-chain antibodies at the surface of the bacterium to affect its tropism favourably. A proof of principle of this approach has recently been demonstrated with Salmonella, 34 where an anti-CEA single-chain antibody was expressed at the surface of the bacterium. 34 Other types of bacteria are currently being developed as anticancer agents. [6] [7] [8] [9] [10] 35 In these strategies, spores of anaerobic bacteria are injected and selectively grow within the necrotic regions of tumours where they find a niche to grow. For example, C. novyi has shown some dramatic antitumour effects in combination with conventional chemotherapeutic drugs 35 and Salmonella are capable of targeting, colonizing and eliciting growth suppression of tumours in mice. 6, 7 Attenuated forms of Salmonella typhimurium have been tested in clinical trials. 11 For most of the bacteria used, the precise mechanism of action remains unclear. However, the anticancer properties of Salmonella are not mediated by invasion of the tumour cells since Salmonella mutants with impaired ability to invade in vitro melanoma cells had no reduction in their antitumour activity in vivo. 36 Therefore, the invasive E. coli described in the present report represent a mechanistically different alternative approach that could be developed in parallel to attenuated, homing anaerobic bacteria.
In addition to its potential clinical applications, invasive E. coli could also be used in vitro as vector for protein delivery in high-throughput screens. Random Invasive E. coli as a therapeutic delivery vector RJ Critchley et al sequence mutagenesis in E. coli has been used to modify the specificity of enzymes for their substrate. For example, in an attempt to create herpes simplex virus type 1 thymidine kinase mutants capable of metabolizing ganciclovir more efficiently, more than 10 6 different clones were created. 37 The screening procedure involved genetic complementation of various E. coli strains to identify mutants with the desired properties and the generation of stable mammalian cell lines to test whether the selected mutants were able to sensitize these cells to ganciclovir. 37 Direct selection of mutant enzymes in highthroughput screenings would become possible by the use of invasive E. coli in target mammalian cells.
In summary, we demonstrate that invasive E. coli are much more efficient as a protein delivery system than a gene delivery system. There is currently no universal procedure to introduce proteins into the living mammalian cells and we expect that the simple method detailed in this study will be applicable for the delivery of many different proteins, for a diverse range of applications that may include the delivery of therapeutically relevant molecules.
Materials and methods
Infection of Caco-2 with invasive bacteria
Caco-2 or HeLa cells were seeded at a density of 1.5 Â 10 4 cells/cm 2 in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS; Autogen Bioclear, Calne, UK) and used the next day. A single colony of bacteria was inoculated in 5 ml of brain heart infusion (BHI) containing the appropriate antibiotics and 0.5 mM dap and grown for 6 h at 301C with shaking. A 1 ml aliquot of this culture was inoculated in 100 ml of BHI þ dap, containing the appropriate antibiotics. The overnight culture (OD 600 ¼ 3) was then used for invasion experiments, unless induction of protein synthesis was performed (see below). The bacteria were centrifuged at 6000 g for 15 min and the resulting pellet was resuspended in DMEM. The number of bacteria was determined spectrophotometrically and the bacterial solution was diluted in DMEM with 10% FCS and 0.5 mM dap at the appropriate concentration. For invasion, Caco-2 cells were washed once with serum-free DMEM and incubated with the bacteria for 2 h at 371C. Cells were then washed three times with serum-free media and re-fed with complete media containing 20 mg/ ml gentamicin to kill extracellular bacteria.
Flow cytometric analysis
Cells were trypsinized and centrifuged for 5 min at 1500 rpm. The pellets were washed twice in PBS and resuspended in 300 ml of PBS, or in some experiments containing 0.5% paraformaldehyde per sample. Flow cytometric analysis was performed on the fixed cells, using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and the data were analysed using CellQuest software (Becton Dickinson).
Cloning and expression of the UPRT gene
The expression of UPRT was performed using the prokaryotic expression vector pBAD/HisA (Invitrogen, Paisley, UK). This vector contains a conditional promoter that is active upon L-arabinose addition to the culture medium. A PCR product containing the upp gene (encoding the UPRT protein, see nucleotide sequence) 38 was cloned from the genome of BM2710 E. coli (primers: 5 0 -ctcgagaagatcgtggaagtcaaacac-3 0 and 5 0 -aagcttttatttcgtaccaaagattttgtc-3 0 ). The XhoI and a HindIII sites flanking the PCR product were used to clone the upp gene into the prokaryotic expression vector pBAD/HisA, in-frame with an N-terminal leader peptide. Part of this peptide is recognized by the Anti-Xpresst antibody (Invitrogen). This plasmid was then transformed into E. coli BM2710 derivative already containing pGB2Oinv-hly. A single E. coli BM2710 pGB2Oinv-hly/upp colony was inoculated into 10 ml of BHI containing dap and grown overnight at 301C under constant agitation. A 1 ml aliquot of the overnight culture was seeded into 100 ml of BHI containing 0.5 mM dap and grown at 301C under agitation until the OD 600 reached 0.5 (mid-log phase of growth). The expression of the UPRT protein was then induced with L-arabinose (0.002% w/v) and the bacteria grown for a further 4 h.
Cell-kill assays
After invasion with the various invasive E. coli at various MOIs, Caco-2 were grown in DMEM containing 10% FCS, 20 mg/ml gentamicin and various concentrations of either 5-FU or 6-MPDR. Viability was assessed by MTT assay 39 after 5 days (unless otherwise stated). The cells were incubated with 0.5 mg/ml MTT for 3 h, dissolved in DMSO and the optical density was read at 540 nm.
Animal experiments
C57/B6J mice were obtained from Harlan (Oxfordshire, UK) and kept in a germ-free environment with irradiated food and acidified water ad libitum. Experiments were conducted after appropriate ethical approval and licensing was obtained in accordance with the UK 'Guidance on the operation of animals (Scientific Procedure) Act 1986' (HMSO, London, UK, 1990).
Female C57/B6J mice aged 6-8 weeks were injected subcutaneously with 5 Â 10 5 B16 cells. When the tumours reached 0.7-1 cm 3 , they were directly injected with PBS, 5 Â 10 6 E. coli BM2710 lacZ or 5 Â 10 6 E. coli BM2710 pGB2Oinv/lacZ (induced to express b-galactosidase as described above). At various time points following the i.t. injections, the mice were killed. The tumours were excised, immersed in isopentane for 20 min at room temperature and snap-frozen in liquid nitrogen. The frozen tumours were sectioned at 5 mm, fixed in 2% formaldehyde for 20 min and stained for b-galactosidase activity.
Assessment of necrosis in subcutaneous tumours
Female C57/B6J mice aged 6-8 weeks were injected subcutaneously with 10 6 Panc-02 cells. When the tumours reached 0.3 Â 0.3 cm, they were directly injected with PBS or 10 8 E. coli BM2710 pGB2Oinv-hly. The i.t. injections were followed 2 h later by i.p. injections with PBS or 100 mg 6-MPDR. After 3 days, the mice were culled, the tumours were removed, immersed in isopentane for 20 min and snap-frozen in liquid nitrogen. Sections (5 mm) were taken from the frozen tumours, acetone-fixed and stained with haematoxylin and eosin. The percentage necrosis of tumours was scored by viewing tumour sections by microscopy ( Â 40 magnification) and estimating the percentage area of necrosis in Invasive E. coli as a therapeutic delivery vector RJ Critchley et al each section. Four sections of five tumours per condition were scored and the mean percentage necrosis was calculated.
IHC staining of macrophages and DCs in tumour sections
Tumour sections were acetone-fixed, washed twice in Tris-buffered saline (TBS), followed by two washes in TBS containing 0.025% Triton to reduce surface tension. Sections were then blocked using TBS supplemented with 20% goat serum (Serotec Ltd, Oxford, UK) for 1 h at room temperature. Sections were incubated with primary rat anti-mouse antibodies (anti-F480 or anti-CD205, Serotec Ltd, Oxford, UK) in TBS þ 5% goat serum at 41C overnight. Sections were washed twice in TBS containing 0.025% Triton, and incubated with a goat anti-rat antibody-HRP (Serotec Ltd, Oxford, UK) for 2 h at room temperature. Slides were washed twice in TBS and developed using 0.5 mg/ml DAB in TBS for 10 min at room temperature, followed by two further washes in TBS. Slides were counterstained with haematoxylin, dehydrated and mounted using Depex mounting medium (BDH Laboratory Supplies, Poole, UK).
b-Galactosidase staining
Briefly, cells or tumour sections were fixed in cold 2% paraformaldehyde for 30 min at 41C. Staining was obtained by adding 5-bromo-4-chloro-3 indolyl b-galactosidase, as described previously. 40 Cell lines SW979, T84, SW850, PT45, Panc-1, Caco-2 and HeLa cells were obtained from the Cancer Research UK cell line collection. Panc-02 cells were kindly provided by Dr Hollingsworth (University of Nebraska Medical Center, Omaha, USA) and the cell line GD25 18 and its b1-integrin-expressing counterpart 19 were provided by Dr R Fassler (Max Planck-Institute for Biochemistry, Germany).
Bacteria
The bacterial strains and plasmids used in this study have been described previously. 12 Briefly, the dap auxotrophic strain E. coli BM2710 was grown in the presence of 0.5 mM dap. The invasion plasmids pGB2Oinv or pGB2Oinv-hly confer resistance to streptomycin and spectinomycin. The plasmid pAT505 (Ampicillin R ) directs synthesis of GFP in E. coli. 12 Bacteria expressing b-galactosidase were obtained by transforming E. coli BM2710 pGB2Oinv or pGB2Oinv-hly with pBAD/HisA/LacZ (Invitrogen) conferring resistance to ampicillin. Expression of the LacZ protein was induced with 0.2% L-arabinose, according to the manufacturer's instructions. The resulting bacteria are referred to as E. coli BM2710 pGB2Oinv-hly/lacZ. Materials 6-MPDR was synthesized as described previously 41 and was kindly provided by Dr GW Both (University of New South Wales, Australia). 5-FU was purchased from David Bull Laboratories (Mulgrave, Australia). Cell lines were obtained from the collection maintained at the Research Cell Service of Cancer Research UK. All other chemicals and reagents were purchased from Sigma-Aldrich (Poole, UK), unless otherwise stated.
